Comparison of Buprenorphine and Methadone - 3

This study has been completed.
Sponsor:
Collaborator:
Washington DC VA
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000334
First received: September 20, 1999
Last updated: June 2, 2015
Last verified: December 2002
  Purpose

The purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.


Condition Intervention Phase
Opioid-Related Disorders
Drug: Buprenorphine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacological Comparison of Buprenorphine and Methadone

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Withdrawal severity
  • Opiate agonist symptoms

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   23 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000334

Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
Washington DC VA
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington DC VA
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000334     History of Changes
Other Study ID Numbers: NIDA-3-0009-3, Y01-3-0009-3
Study First Received: September 20, 1999
Last Updated: June 2, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Buprenorphine
Analgesics
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 01, 2015